Lyfegen is a global healthtech SaaS company driving the world's transition from volume to value-based healthcare for high-cost drugs.
Lyfegen provides a value and outcome-based agreement platform for Health Insurances, Pharma, MedTech & Hospitals around the globe.
Lyfegen was founded in 2018 by Nico Mros, Michel Mohler, Girisha Fernando, and Leon Rebolledo. The company is headquartered in Basel, Switzerland, with an office in Washington, DC.
Lyfegen's platform helps regulators, pharma companies and payers more easily adopt value-based payment models by digitizing the end-to-end process of data collection, anonymization and contract negotiations for all parties to agree upon drug pricing and reimbursement.
Lyfegen's patent-pending, ground-breaking software analyses complex healthcare data sets in order to help patients access innovative therapies that focus on the healthcare outcomes that matter most to them.
Lyfegen's value-based contracting software is used by healthcare payers and leading pharma companies, including Novartis, Roche, MSD, Bristol Myers Squibb (BMS) and Johnson & Johnson
Lyfegen is backed by aMoon, APEX Ventures, and others. The company raised an oversubscribed $8M Series A round on Sep 20, 2022. This brings Lyfegen's total funding to $10.9M to date.